Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

The New England Journal of Medicine
John J V McMurrayDAPA-HF Trial Committees and Investigators


In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes. In this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death. Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in ...Continue Reading


Apr 12, 2000·Journal of the American College of Cardiology·C P GreenJ A Spertus
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Mar 11, 2015·European Journal of Heart Failure·John J V McMurray
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Mar 13, 2016·Pharmaceutical Statistics·Duolao Wang, Stuart Pocock
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Feb 28, 2018·Circulation·Karen A HicksUNKNOWN Standardized Data Collection for Cardiovascular Trials Initiative (SCTI)
Aug 23, 2018·Diabetologia·Subodh Verma, John J V McMurray
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Apr 17, 2019·The New England Journal of Medicine·Vlado PerkovicUNKNOWN CREDENCE Trial Investigators
Jul 17, 2019·European Journal of Heart Failure·John J V McMurrayUNKNOWN DAPA-HF Committees and Investigators

❮ Previous
Next ❯


Oct 4, 2019·Nature Reviews. Cardiology·Karina Huynh
Nov 14, 2019·Journal of Diabetes·Zachary Bloomgarden, Yehuda Handelsman
Sep 20, 2019·The New England Journal of Medicine·James C Fang
Nov 19, 2019·Expert Opinion on Drug Discovery·Adrián M RamosAlberto Ortiz
Dec 18, 2019·JAMA : the Journal of the American Medical Association·Gregory Curfman
Dec 24, 2019·Hypertension·Flávio D Fuchs, Paul K Whelton
Jan 4, 2020·European Heart Journal·John J V McMurrayPardeep S Jhund
Jan 7, 2020·Journal of Clinical Pharmacy and Therapeutics·Theocharis KoufakisKalliopi Kotsa
Nov 18, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Anastasia Erythropoulou-KaltsidouKonstantinos Tziomalos
Nov 27, 2019·International Journal of Molecular Sciences·Linda Wu, Jenny E Gunton
Jan 26, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Junichi OkadaMasanobu Yamada
Feb 1, 2020·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Claire C J Dekkers, Ron T Gansevoort
Dec 22, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·David M WilliamsMarc Evans
Feb 6, 2020·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez
Feb 6, 2020·European Journal of Heart Failure·Nicholas R JonesF D Richard Hobbs
Feb 25, 2020·European Journal of Preventive Cardiology·Justin Parizo, Kenneth W Mahaffey
Feb 28, 2020·Circulation Research·Jingjing CaiHongliang Li
Jan 25, 2020·Journal of Cardiovascular Medicine·Dimitrios PatouliasMichael Doumas
Jan 12, 2020·European Journal of Heart Failure·Pardeep S Jhund
Mar 3, 2020·European Journal of Heart Failure·Andrew J S Coats
Mar 5, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay KalraJignesh K Ved
Mar 5, 2020·The New England Journal of Medicine·Jefferson L Vieira, Mandeep R Mehra
Jan 10, 2020·Future Cardiology·Dalal Y Al-Bazz, John Ph Wilding
Mar 8, 2020·Cardiology and Therapy·Ian B A MenownUwe Zeymer
Mar 8, 2020·Pflügers Archiv : European journal of physiology·Volker Vallon
Jan 17, 2020·The Journal of Clinical Endocrinology and Metabolism·João Sérgio NevesFinnian R Mc Causland
Mar 15, 2020·International Journal of Molecular Sciences·Yoshio SumidaJapan Study Group Of Nafld Jsg-Nafld

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Related Papers

The New England Journal of Medicine
John J V McMurrayPARADIGM-HF Investigators and Committees
The New England Journal of Medicine
Stephen D WiviottDECLARE–TIMI 58 Investigators
The New England Journal of Medicine
John J V McMurrayATMOSPHERE Committees Investigators
The New England Journal of Medicine
Rury R HolmanEXSCEL Study Group
© 2022 Meta ULC. All rights reserved